Colectomy and liver transplantation alter disease behavior in IBD-Associated PSC, highlighting unique risks and challenges. PSC patients face heightened cancer risk after colectomy, while transplant reshapes risks of de novo IBD and recurrent PSC.
A multinational study found PSC prevalence among Asian IBD patients to be markedly lower than in Western countries, associated with more favorable clinical outcomes. The proportion of asymptomatic PSC cases has increased due to improved imaging modality detection, allowing for early-stage diagnosis and reduced liver transplantation rates.
The coralME tool creates detailed genome-scale models of metabolism, gene and protein expression from large amounts of data. The models uncover how microbes respond to certain nutrients and predict what nutrients favor the formation of undesired products.
The American Gastroenterological Association has released an updated clinical guideline on the pharmacological management of moderate-to-severe Crohn’s disease, recommending early use of high-efficacy therapies to improve patient outcomes. The guideline organizes treatments by efficacy to simplify decision-making for gastroenterologist...
Renowned gastroenterologist Jean-Frédéric Colombel, MD, will deliver the 31st Anatomy Lesson on November 20, exploring Mount Sinai's pioneering work in IBD prevention and treatment. His presentation aims to highlight the growing problem of immune diseases, including Crohn's disease.
Research from the University of Gothenburg has identified two bacteria that can produce bioactive serotonin, a key player in bowel movements and brain function. These findings suggest new avenues for treating functional gastrointestinal disorders like IBS.
Researchers analyzed 659 posts on Reddit to better understand the role of social media in managing inflammatory bowel disease. The study found that patients use social media to track symptoms, manage medications, and cope with stress.
Double negative T cells (DNT cells) play an indispensable role in suppressing intestinal inflammation, acting as antigen-presenting cells. Their impaired function may contribute to the pathogenesis of Crohn’s disease, suggesting they could be a potential therapeutic target.
Researchers at uOttawa are developing an AI tool to provide personalized dietary strategies for people living with inflammatory bowel disease (IBD). The project aims to match specific types of carbohydrates to individual patients' unique gut microbiomes.
A UCLA Health study found that taking an 8-strain probiotic daily reduces the risk of pouchitis, a common inflammatory condition. However, the treatment's cost-effectiveness depends on the patient's likelihood of flare-ups, with benefits only seen in patients with frequent relapses.
This study identifies ulcerative colitis as the most common subtype of IBD in Nigeria, with rectal bleeding being the predominant clinical feature. The findings highlight significant management challenges due to high medication costs and limited availability, affecting nearly half of patients.
A new study published in Clinical Gastroenterology and Hepatology shows that AI analysis can accurately identify mucosal ulceration as well as human reviewers, providing a more objective and reproducible assessment of Crohn's disease. The findings have potential implications for education, drug development, and automated care.
Researchers discovered that inflammatory bowel disease (IBD) leads to blood clotting due to a lack of layilin protein, which prevents platelets from forming unwanted clots. A drug targeting Rac1 activity could reduce excessive clotting and alleviate day-to-day IBD symptoms.
Researchers discovered that smoking produces metabolites that encourage mouth bacteria to grow in the large intestines, triggering an immune response. These bacteria, specifically Streptococcus mitis, help reduce inflammation in ulcerative colitis by triggering a specific immune response.
A large-scale study published in PLOS Medicine found no association between early life antibiotic exposure and the development of autoimmune diseases in children. Researchers analyzed data from over 4 million Korean children and discovered no increased risk of Type 1 diabetes, Juvenile idiopathic arthritis, or other autoimmune conditions.
A new study published in Molecular Nutrition and Food Research found that red meat consumption causes an imbalance of bacteria in the intestinal microbiota, leading to exacerbated colonic inflammation. The diets resulted in a decrease in beneficial bacterial strains and an increase in pro-inflammatory cells.
The study found substantial interrater reliability for active disease grades, but variability in individual grade assignments. The NHI showed substantial interrater reliability (ICC = 0.79) among US gastrointestinal pathologists for assessing histologic remission in treated ulcerative colitis biopsies.
Researchers discovered a new pathway to boost immunity against parasitic infections, suggesting that NSAIDs like ibuprofen could be repurposed as anti-parasitic treatments. Gasdermin C plays a crucial role in this process, targeting and penetrating Rab7-positive vesicles to reduce prostaglandin d2 levels.
A study by University of California, Riverside researchers found that inhaling agricultural dust can alter the gut microbiome and impair intestinal function, leading to increased 'leaky gut' and associated chronic diseases. The study highlights the need for protective measures for agricultural workers.
A study reveals that a combination of dysbiosis, OTUD3 gene mutations, and STING signaling aggravate ulcerative colitis. The intestinal flora plays a vital role in UC, but an unbalanced microbiome with fewer beneficial microbes and more harmful ones contributes to the disease.
A large prospective study found that a healthy plant-based diet is associated with an 8% lower risk of ulcerative colitis and a 14% lower risk of Crohn’s disease. Fruits and vegetables were identified as key protective factors against inflammatory bowel disease.
A new online program aims to improve body image and wellbeing for people with Inflammatory Bowel Disease (IBD). The 10-module program uses mindfulness techniques, cognitive behavioural therapy, and self-compassion training to help patients overcome negative thought patterns and social comparisons.
A large-scale study found no association between medication use and the development of microscopic colitis, contradicting previous findings. SSRIs were linked to a slightly higher risk, but also increased the likelihood of receiving a colonoscopy.
The study found that significant changes in sleep metrics occurred only when inflammation was present in the body, with symptoms alone not resulting in any notable sleep disruption. Sleep disturbances worsened leading up to inflammatory flares and improved afterward, suggesting that sleep changes may signal upcoming disease activity.
Researchers have discovered that supplementing with isobutyrate eases intestinal inflammation and restores gut balance in a pig model of colitis. The study shows that isobutyrate shifts the microbiome toward beneficial bacteria, reduces diarrhea and bleeding, and strengthens the intestinal barrier.
Damage to the intestinal barrier is a key factor in IBD pathogenesis. The barrier maintains homeostasis by preventing harmful substances from entering systemic circulation. Emerging therapeutic strategies target oxidative stress modulation, microbiota restoration, and autophagy regulation.
This article highlights the regulatory effects of copper metabolism on cuproptosis in intestinal diseases like colitis and carcinogenesis. Cuproptosis exhibits a bidirectional regulatory role in modulating oxidative stress responses, metabolic reprogramming, and immunotherapeutic efficacy.
Recent research highlights the gut microbiome's pivotal role in IBD pathogenesis, alongside metabolomic and immunological dysregulation. An integrative model links microbiome shifts to reduced butyrate, disrupting Th17/Treg balance and elevating IL-6/IL-17.
New research warns against widespread use of Fecal Microbiota Transplants (FMT) due to potential for long-lasting, unintended health consequences. Mismatches in gut ecosystems can lead to changes in metabolism, behavior, and energy balance.
Researchers identified a gene mutation that disrupts iron absorption in patients with Crohn's disease, leading to persistent anemia. The study sheds light on how genetic risk factors for IBD can compound patient symptoms by interfering with nutrient absorption.
A study in Gastroenterology Nursing found that popular IBD-related TikTok videos have very low scores for quality of medical information, despite their high views. The research suggests that tailored educational content on IBD can be created for the platform, addressing gaps in IBD education.
A pioneering research brings psychedelic medicine into gastroenterology, exploring psilocybin's effects on treatment-resistant irritable bowel syndrome (IBS). Dr. Erin E. Mauney's study modulates interoception and uses integrated therapy sessions with neuroimaging to track brain changes.
This study investigates UGIT involvement in adult Egyptian UC patients, finding significant esophagitis and gastritis. The results demonstrate a strong association between colonic disease severity and UGIT endoscopic and histopathological findings.
A global study describes four distinct stages of inflammatory bowel disease (IBD) as it spreads to newly developing regions in Africa, Asia, and Latin America. The research provides resources and guidance for local healthcare systems coping with the growing burden of IBD patients.
Research in rats suggests that Arbutus unedo extract can prevent changes in the colon's lining and reduce colonic lesions. The treatment also caused decreased expression of proteins promoting oxidative stress and inflammation.
Researchers at The University of Osaka found that localized oxygen deficiency in colon tumors can promote tumor growth by transforming normal fibroblasts into inflammatory fibroblasts. These altered cells release factors that help tumors grow, offering a potential new target for cancer therapy.
Researchers find inhibiting TMEM219 signaling restores mucosal healing in inflammatory bowel diseases and protects intestinal stem cells from death. The study suggests TMEM219 overactivation induces intestinal stem cell death, preventing mucosal renewal during inflammation.
A new approach, GlycoCaging, delivers medicine directly to the lower gut at significantly lower doses than current treatments, potentially helping people with inflammatory bowel disease. The technique has been shown to be effective in mice and has potential for treatment in humans, as most people have the ability to activate the drugs.
Researchers from UCalgary and Chinese University of Hong Kong found that IBD progresses through four predictable epidemiological stages as it spreads globally. The study forecasts a major rise in IBD prevalence in Canada by 2045, with countries in North America, Europe, and Oceania reaching Stage 3 (compounding prevalence). Developing ...
Preet Chaudhary and Michael Selsted, USC innovators, recognized by the National Academy of Inventors for their work on harnessing the power of the immune system. Their research aims to develop new treatments for diseases such as cancer, rheumatoid arthritis, and sepsis.
A longitudinal study found that EBV infection predisposes people to develop Crohn's disease, with a five-to-seven-year delay between exposure and diagnosis. The study suggests that EBV may alter the immune system leading to Crohn's disease.
Researchers at U of T discover a ginger compound called furanodienone that selectively binds to and regulates nuclear receptor PXR, reducing inflammation in the colon. FDN has been shown to increase tight junction proteins, repairing damage to the gut lining caused by inflammation.
Researchers at Virginia Tech have developed a method to convert gut bacteria into mini protein factories that produce and release sustained flows of targeted proteins within the lower intestine. This approach eliminates a major roadblock in delivering drugs to this part of the body, offering potential treatment for chronic diseases.
Researchers at Virginia Tech have developed a way to convert gut bacteria into miniature protein factories that produce and release targeted proteins inside the lower intestine. This breakthrough could potentially treat chronic diseases.
A new Weizmann Institute study identified all proteins in a stool sample – those from the microbiome, human body, and food – revealing secrets of the intestines and their impact on human disease. The method, dubbed IPHOMED, decodes microbiome activity by showing which proteins come from bacterial strains and amounts.
Researchers at Duke University School of Medicine found that vagus nerve stimulation reduces gut inflammation by modulating immune response, potentially offering new IBD therapies. The study showed improved symptoms and boosted survival rates in stressed mice with colitis.
Researchers at Karolinska Institutet have identified a molecule that can promote mucosal healing through tissue regeneration, potentially treating inflammatory bowel disease and colorectal cancer. The study found that activation of the Liver X receptor suppresses tumor growth in colorectal cancer, offering new therapeutic strategies.
The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis. The guideline groups available treatments into 'efficacy buckets' to facilitate personalized treatment planning, taking into account patient risk factors and disease severity.
A new UC Davis Health study has uncovered the mechanisms by which Salmonella bacteria evade the body's natural defenses in the gut. The research found that Salmonella alters the gut's nutrient environment to fuel its replication in the large intestine, creating an imbalance that helps the pathogen survive. This new understanding could ...
The winners of the Applied Microbiology International Horizon Awards 2024 have been named, including the One Health Microbiome Center at Penn State and researchers Dr. François Thomas and Dr. Helen Onyeaka.
Researchers from UT Arlington sequenced RNA genes of pythons, discovering conserved pathways in humans that are activated uniquely by these snakes. This knowledge helps explain intestinal regeneration and metabolism changes, offering potential therapeutic targets.
A team of researchers has identified a genetic variant associated with severe ulcerative colitis, which may help predict patient outcomes and guide targeted treatment approaches. The study found that patients carrying the HLA-DRB1*01:03 variant were more likely to require major surgery within three years of diagnosis.
Researchers identified T. immunophila as a key player in breaking down the gut's protective immune barrier, leading to increased susceptibility to pathogens and delayed repair of the gut barrier. The discovery provides a promising new avenue for treatment of inflammatory bowel disease, Crohn's, and ulcerative colitis.
A large study found that women with premature ovarian insufficiency are 2.6 times more likely to have an autoimmune disorder, with some conditions increasing the risk by 26 times. The study suggests a strong link between POI and severe autoimmune diseases, highlighting the need for medical professionals to be aware of this increased risk.
Researchers have identified 18 beneficial bacterial strains that suppress the growth of harmful bacteria and alleviate inflammation in mouse intestines. The strains compete with harmful bacteria for nutrients, promoting a healthier intestinal microbiome and potentially treating antibiotic-resistant gut infections.
Researchers have discovered a new class of natural antimicrobials called microcins that can target specific strains of bacteria causing cholera, inflammatory bowel disease, and colon cancer. Microcins are highly selective and can potentially remove unwanted bacteria without disrupting the human gut microbiome.
A new study published in Science Advances has found that antibiotics disrupt the protective mucus layer in the intestine, increasing the risk of inflammatory bowel disease. Researchers discovered that antibiotics damage the mucus barrier in a microbiota-independent manner, facilitating bacterial penetration and gut inflammation.
A new narrow-spectrum antibiotic, FP 100, has been found to effectively eliminate Fusobacterium nucleatum without harming the oral or gut microbiomes. This breakthrough discovery holds significant implications for treating severe gum disease and preventing related systemic conditions such as colon cancer and Alzheimer's disease.
This study found modestly increased risks of inflammatory bowel disease and bullous skin disorders in hospitalized patients infected with the Omicron variant. Booster vaccination mitigated long-term autoimmune sequelae risk.
Researchers discovered a unique probiotic strain, Bifidobacterium bifidum BB1, that strengthens intestinal barrier function and protects against harmful bacteria. This strain may lead to the development of novel therapies for patients with inflammatory bowel disease and other inflammatory conditions.